← 返回首页
美国 · 经济杂志 · Markets Insider (Business Insider)

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of...

来源：Markets Insider (Business Insider) · 美国 1 小时前

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and…

在 Markets Insider (Business Insider) 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (markets.businessinsider.com)

推荐阅读

Kiplinger

3 Changes to Treasury Direct You Need to Know

 Inc.

Emma Grede Built Good American Around Jeans. Now She’s Thinking Bigger

 Entrepreneur

Wendy’s Hopes to Win Back Customers by Serving Up the Past With Its ‘Iconic’ Dave’s Single Combo Meal for $7.99

 Quartz

Jensen Huang pushed back on 2029 memory glut fears amid stock selloff

 Fortune

My industry wants you to fire your sales team. One of my customers plans to double theirs

 Fast Company

American Express and Airbnb just announced a major partnership. Here’s what changes for cardholders